As part of PharmTech’s coverage of CPHI Milan, Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, ...
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains that developing a molecule requires a ...
Sanofi and Cheplapharm have announced plans for a strategic partnership that would transfer 20 mature medicines and three ...
High-concentration biologics are pushing the limits of what can be formulated, filled, and delivered as a low-volume ...
Keshav Bhutada, chief executive officer of Shilpa CDMO, said the company has long been recognized among existing partners for its capabilities with challenging molecules such as high-potency APIs ...
Christy Owings, vice president and general manager of the Americas business unit, Thermo Fisher Scientific, connected with ...
Since July 2026, the European Union (EU) has shifted its focus from legislative reforms to practical applications, prioritizing supply-chain resilience, preventing medicine shortages, streamlining ...
Christy Owings, vice president and general manager of the Americas business unit at Thermo Fisher Scientific, discusses with ...
Novartis obtained portfolio-level options for exclusive rights to Hybrozyme-enabled SC formulations, with economics up to ...
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol ...
Tara Dougal, event director for pharma at Informa Markets and head of CPHI Milan, previews the 2026 show in an interview with ...
On PharmTech.com this week, coverage of upcoming events continued, experts continued to discuss the use of AI in pharma, and validation in oral solid dosage product production was emphasized.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results